rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Adam Koppel

Director and 10% owner

Company insider

Files Form 4 as: Director and 10% owner, Kailera Therapeutics; Director and 10% owner, Cerevel Therapeutics Holdings; Director, Foghorn Therapeutics; Director and 10% owner, Solid Biosciences; Director and 10% owner, Aptinyx; Director and 10% owner, Dicerna Pharmaceuticals; 10% owner, SpringWorks Therapeutics; Director and 10% owner, BCLS Acquisition.

Every Form 4 they filed

In numbers

Trades disclosed
117
Buys
9
Sells
5
Bought
$323.4M
Sold
$164.3M
Companies
12
Companies where not an officer
11
First trade
7 Mar 2013
Last trade
20 Apr 2026
Last filed
20 Apr 2026

Companies traded

Where they are an officer
BIIB BiogenOfficer · Biotechnology · last 6 Jun 20160 buys · 2 sells
Everywhere else they filed: board seats, 10% stakes, other companies
KLRA Kailera TherapeuticsDirector, 10% owner · Biotechnology · last 20 Apr 20261 buy · 0 sells
Cerevel Therapeutics HoldingsDirector, 10% owner · last 1 Aug 20243 buys · 0 sells
FHTX Foghorn TherapeuticsDirector · Biotechnology · last 26 Jun 20240 buys · 0 sells
SLDB Solid BiosciencesDirector, 10% owner · Biotechnology · last 11 Jan 20241 buy · 0 sells
AptinyxDirector, 10% owner · last 26 May 20222 buys · 0 sells
Dicerna PharmaceuticalsDirector, 10% owner · last 28 Dec 20210 buys · 2 sells
SpringWorks Therapeutics10% owner · last 9 Mar 20210 buys · 1 sell
BCLS AcquisitionDirector, 10% owner · last 26 Oct 20200 buys · 0 sells
ARQT Arcutis Biotherapeutics10% owner · Biotechnology · last 4 Feb 20201 buy · 0 sells
TrevenaDirector · last 16 May 20180 buys · 0 sells
PTCT PTC TherapeuticsDirector · Biotechnology · last 3 Jan 20171 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
01Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
20 Apr 2026filed 20 Apr 2026KLRA Kailera TherapeuticsBiotechnologySEC FORM 4 Code C—16,875,000filing
20 Apr 2026filed 20 Apr 2026KLRA Kailera TherapeuticsBiotechnologySEC FORM 4 Code C—4,145,768filing
20 Apr 2026filed 20 Apr 2026KLRA Kailera TherapeuticsBiotechnologySEC FORM 4 Bought$25.0M1,562,500 at $16.00filing
20 Apr 2026filed 20 Apr 2026KLRA Kailera Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—16,875,000 at $0.00filing
20 Apr 2026filed 20 Apr 2026KLRA Kailera Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—4,145,768 at $0.00filing
20 Apr 2026filed 20 Apr 2026KLRA Kailera Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—16,875,000 at $0.00filing
20 Apr 2026filed 20 Apr 2026KLRA Kailera Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—4,145,768 at $0.00filing
20 Apr 2026filed 20 Apr 2026KLRA Kailera TherapeuticsBiotechnologySEC FORM 4 Code C—16,875,000filing
20 Apr 2026filed 20 Apr 2026KLRA Kailera TherapeuticsBiotechnologySEC FORM 4 Code C—4,145,768filing
20 Apr 2026filed 20 Apr 2026KLRA Kailera TherapeuticsBiotechnologySEC FORM 4 Bought$25.0M1,562,500 at $16.00filing
16 Apr 2026filed 20 Apr 2026KLRA Kailera Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—38,300 at $0.00filing
16 Apr 2026filed 20 Apr 2026KLRA Kailera Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—38,300 at $0.00filing
1 Aug 2024filed 5 Aug 2024Cerevel Therapeutics Holdingsoption or derivativeSEC FORM 4 Code D—80,189filing
1 Aug 2024filed 5 Aug 2024Cerevel Therapeutics HoldingsSEC FORM 4 Code D—3,282filing
1 Aug 2024filed 5 Aug 2024Cerevel Therapeutics HoldingsSEC FORM 4 Code D—10,461filing
1 Aug 2024filed 5 Aug 2024Cerevel Therapeutics HoldingsSEC FORM 4 Code D—65,679,781filing
26 Jun 2024filed 28 Jun 2024FHTX Foghorn Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A$88K16,000 at $5.52filing
5 Jun 2024filed 7 Jun 2024Cerevel Therapeutics HoldingsSEC FORM 4 Code A—10,461filing
11 Jan 2024filed 12 Jan 2024SLDB Solid BiosciencesBiotechnologySEC FORM 4 Code A$5.0M904,160 at $5.53filing
16 Oct 2023filed 18 Oct 2023Cerevel Therapeutics HoldingsSEC FORM 4 Bought$125.0M5,480,052 at $22.81filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care6
Not placed8

Buys in green, sells in red, by the company’s sector.

Related people

Sean GodboutChief Accounting Officer · Chief Accounting Officer at Biogen, filing Form 4 there in the last year
Michael PariniChief Legal Officer · Chief Legal Officer at Biogen, filing Form 4 there in the last year
Lloyd MinorDirector · Director at Biogen, filing Form 4 there in the last year
Maria C. FreireDirector · Director at Biogen, filing Form 4 there in the last year
Jesus B. MantasDirector · Director at Biogen, filing Form 4 there in the last year
Gabriel BrooksChief Medical Officer · Also traded SLDB in the last 90 days
Howard G. WelgusDirector · Also traded ARQT in the last 90 days
Michael SchmertzlerDirector · Also traded PTCT in the last 90 days